J&J’s new psoriasis pill could reshape the treatment landscape
TL;DR Summary
Johnson & Johnson won U.S. approval for Icotyde, a daily oral medication for moderate-to-severe plaque psoriasis in patients 12 and older, designed to mimic the effects of top-selling injectables like Skyrizi and Tremfya without injections. The pill could expand the patient market and is projected to reach more than $5 billion in peak annual sales, potentially reshaping competition in a multibillion-dollar field.
- J&J wins approval for first-of-its-kind psoriasis pill | STAT statnews.com
- FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi CNBC
- US FDA approves J&J's oral psoriasis pill Reuters
- J&J, Protagonist's 'game-changer' once-daily psoriasis pill Icotyde nabs FDA approval Fierce Pharma
- FDA Approves Icotrokinra, First Oral IL-23 Inhibitor for Plaque Psoriasis The American Journal of Managed Care® (AJMC®)
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
2 min
vs 3 min read
Condensed
86%
442 → 62 words
Want the full story? Read the original article
Read on statnews.com